Cas No.: | 2360851-29-0 |
SMILES: | O=C1NC(CS[C@H]2CC[C@H](O)CC2)=NC3=C1C(F)=CC(OCC4CC4)=C3 |
Formula: | C19H23FN2O3S |
M.Wt: | 378.46 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | RBN012759 is a potent, selective and orally active inhibitor of PARP14, with an IC50 of <3 nM. RBN012759 displays 300-fold selectivity over the monoPARPs and 1000-fold selectivity over the polyPARPs. RBN012759 decreases pro-tumor macrophage function and elicits inflammatory responses in tumor explants[1]. |
Target: | PARP14:<3 nM (IC50) PARP4:10 μM (IC50) PARP5a:8 μM (IC50) PARP5b:10 μM (IC50) PARP6:4 μM (IC50) PARP7:4 μM (IC50) PARP8:20 μM (IC50) PARP10:1 μM (IC50) PARP11:1 μM (IC50) PARP12:5 μM (IC50) PARP15:3 μM (IC50) PARP16:6 μM (IC50) |
In Vivo: | RBN012759 (500 mg/kg BID; p.o.) is well-tolerated in mice with repeat dosing[1]. RBN012759 (100 mg/kg; p.o.) exhibits moderate orally bioavailability (30%) and short plasma half-life (0.4 h) due to moderate clearance (54 mL/min/kg) and low steady-state volume of distribution (1.4 L/kg) in mice[1]. |
In Vitro: | RBN012759 (0.01-10 μM) decreases the MAR/PAR signal corresponding to PARP14 self MARylation and stabilizes PARP14 protein in a dose-dependent manner in human primary macrophages[1]. RBN012759 (0.1-10 μM) reduces IL-4 stimulated cytokine secretion in human primary macrophages[1]. |
References: | [1]. Schenkel L, et, al. A potent and selective PARP14 inhibitor decreases pro-tumor macrophage function and elicits inflammatory responses in tumor explants. AACR Annual Meeting 2020 |